RESUMO
The authors compared demographic aspects and profile of mutations in 80 patients with subtypes B and F of human immunodeficiency type 1 (HIV-1). Genotyping of the pol region of the reverse transcriptase was performed using the ViroSeq Genotyping System. A total of 61 (76.2%) patients had subtype B and 19 (23.8%) subtype F of the HIV-1. Subtype F tended to be more frequent in heterosexuals and women with a low educational level, but without statistical significance. The frequency of mutations related to nucleoside reverse transcriptase inhibitors and protease inhibitors (PI) was the same in the two subtypes, but mutations related to PI at the codons 63, 77, and 71 were more frequent in subtype B, while mutations at the codons 36 and 20 predominated in subtype F. Sixty-two of the 80 patients infected with subtypes B and F were submitted to antiretroviral therapy for an average of 18-22 months. Undetectable viral loads at the end of follow-up were similar in the two groups, representing 63.8% of subtype B and 73.3% of subtype F (p = 0.715). CD4 lymphocyte counts before and after treatment were similar in the two groups. This study, despite pointing to possible epidemiological and genetic differences among subtypes B and F of HIV-1, suggests that the use of highly active antiretroviral therapy is equally effective against these subtypes.
Assuntos
Fármacos Anti-HIV/uso terapêutico , Infecções por HIV/virologia , Protease de HIV/genética , Transcriptase Reversa do HIV/genética , HIV-1 , Mutação , Terapia Antirretroviral de Alta Atividade , Contagem de Linfócito CD4 , Feminino , Infecções por HIV/tratamento farmacológico , HIV-1/efeitos dos fármacos , HIV-1/genética , Humanos , Masculino , RNA Viral/genética , Carga ViralRESUMO
The authors compared demographic aspects and profile of mutations in 80 patients with subtypes B and F of human immunodeficiency type 1 (HIV-1). Genotyping of the pol region of the reverse transcriptase was performed using the ViroSeqTM Genotyping System. A total of 61 (76.2 percent) patients had subtype B and 19 (23.8 percent) subtype F of the HIV-1. Subtype F tended to be more frequent in heterosexuals and women with a low educational level, but without statistical significance. The frequency of mutations related to nucleoside reverse transcriptase inhibitors and protease inhibitors (PI) was the same in the two subtypes, but mutations related to PI at the codons 63, 77, and 71 were more frequent in subtype B, while mutations at the codons 36 and 20 predominated in subtype F. Sixty-two of the 80 patients infected with subtypes B and F were submitted to antiretroviral therapy for an average of 18-22 months. Undetectable viral loads at the end of follow-up were similar in the two groups, representing 63.8 percent of subtype B and 73.3 percent of subtype F (p = 0.715). CD4 lymphocyte counts before and after treatment were similar in the two groups. This study, despite pointing to possible epidemiological and genetic differences among subtypes B and F of HIV-1, suggests that the use of highly active antiretroviral therapy is equally effective against these subtypes.
Assuntos
Feminino , Humanos , Masculino , Fármacos Anti-HIV/uso terapêutico , Infecções por HIV/virologia , Protease de HIV/genética , Transcriptase Reversa do HIV/genética , HIV-1 , Mutação , Terapia Antirretroviral de Alta Atividade , Infecções por HIV/tratamento farmacológico , HIV-1 , RNA Viral/genética , Carga ViralRESUMO
To assess the prevalence of primary resistance of human immunodeficiency virus type 1 (HIV-1) to antiretrovirals, 84 patients chronically infected with HIV without prior antiretroviral treatment from Northeast Brazil were studied. Genotyping was performed using the ViroSeqTM Genotyping System. Thimidine analog mutations occurred in 3 (3.6 percent) patients. Accessory mutations related to NRTI occurred in 6 (7.1 percent) and related to PI in 67 (79.8 percent). Subtypes B (72.6 percent), F (22.6 percent), B/F 3 (3.6 percent), and C (1.2 percent) were detected. A low prevalence of major mutations related to NRTI in patients chronically infected by HIV was observed.
Assuntos
Humanos , Masculino , Feminino , Adolescente , Adulto , Fármacos Anti-HIV/uso terapêutico , Farmacorresistência Viral/genética , Infecções por HIV/virologia , HIV-1 , Brasil , Doença Crônica , Genótipo , Infecções por HIV/tratamento farmacológico , Protease de HIV/genética , Transcriptase Reversa do HIV , HIV-1 , Mutação , Reação em Cadeia da Polimerase , Prevalência , Timidina/genéticaRESUMO
Os autores trataram 70 pacientes portadores de estrongiloidíase, ascaríase, tricuríase e ancilostomíase com dose única de ivermectina (200 ug/kg). A cura parasitológica obtida foi de 95 porcento para estrongiloidíase, de 100 poecento para ascaríase e tricuríase e de 60 porcento para ancilostomíase. As reaçöes adversas foram observadas em 3 porcento dos pacientes - cefaléia, náuseas e vômitos.(au)
Assuntos
Humanos , Masculino , Feminino , Ancilostomíase/tratamento farmacológico , Ascaríase/tratamento farmacológico , Estrongiloidíase/tratamento farmacológico , Enteropatias Parasitárias , Ivermectina , Tricuríase/tratamento farmacológicoRESUMO
Os autores realizaram uma atualizaçäo clínica, laboratorial e terapêutica sobre a himenolepíase e em seguida apresentam sua prevalência no Hospital das Clínicas da UFPE, Brasil
Assuntos
Biologia , Prevalência , Evolução Biológica , Himenolepíase/diagnóstico , Himenolepíase/etiologia , Himenolepíase/terapia , Praziquantel , Cestoides , Helmintíase/diagnóstico , Helmintíase/etiologia , Helmintíase/terapia , Infecções por CestoidesRESUMO
Os autores fazem uma atualizaçäo sobre isosporíase humana e abordam os principais aspectos da parasitose: epidemiologia, quadro clínico, diagnóstico laboratorial e terapêutica clínica
